OBJECTIVES: Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of the HIV-1 viral load. METHODS: MONOI is a prospective, open-label, non-inferiority, randomized, 96 week trial comparing darunavir/ritonavir monotherapy versus a darunavir/ritonavir triple-therapy strategy to maintain HIV-1 viral load suppression in HIV-1-infected patients. CLINICAL TRIAL REGISTRATION: NCT00412551. RESULTS:From 225 randomized patients, 219 patients reached the 48 week follow-up and 211 reached the 96 week follow-up (106 patients in the darunavir monotherapy arm and 105 in the darunavir triple-therapy arm). Baseline characteristics were well balanced between the two treatment groups. At week 96, in intent-to-treat analysis, 91/103 patients (88%, 95% CI 81-94) allocated to the darunavir/ritonavir monotherapyarm and 87/104 patients (84%, 95% CI 75-90) allocated to the darunavir triple-therapy arm achieved an HIV-1 viral load <50 copies/mL, with no statistical difference between the two groups. Throughout the 96 week follow-up, 66/112 patients (59%, 95% CI 49-68) and 79/113 patients (70%, 95% CI 61-78) consistently had HIV-1 RNA <50 copies/mL with darunavir/ritonavir monotherapy and darunavir/ritonavir triple therapy, respectively. CONCLUSIONS: The MONOI study establishes darunavir/ritonavir monotherapy as durable and efficacious for maintaining virological suppression in HIV-1 patients. Darunavir/ritonavir monotherapy should be considered as a (tailored) treatment option for standard triple-therapy patients who have had a substantial period of viral suppression.
RCT Entities:
OBJECTIVES: Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of the HIV-1 viral load. METHODS: MONOI is a prospective, open-label, non-inferiority, randomized, 96 week trial comparing darunavir/ritonavir monotherapy versus a darunavir/ritonavir triple-therapy strategy to maintain HIV-1 viral load suppression in HIV-1-infectedpatients. CLINICAL TRIAL REGISTRATION: NCT00412551. RESULTS: From 225 randomized patients, 219 patients reached the 48 week follow-up and 211 reached the 96 week follow-up (106 patients in the darunavir monotherapy arm and 105 in the darunavir triple-therapy arm). Baseline characteristics were well balanced between the two treatment groups. At week 96, in intent-to-treat analysis, 91/103 patients (88%, 95% CI 81-94) allocated to the darunavir/ritonavir monotherapy arm and 87/104 patients (84%, 95% CI 75-90) allocated to the darunavir triple-therapy arm achieved an HIV-1 viral load <50 copies/mL, with no statistical difference between the two groups. Throughout the 96 week follow-up, 66/112 patients (59%, 95% CI 49-68) and 79/113 patients (70%, 95% CI 61-78) consistently had HIV-1 RNA <50 copies/mL with darunavir/ritonavir monotherapy and darunavir/ritonavir triple therapy, respectively. CONCLUSIONS: The MONOI study establishes darunavir/ritonavir monotherapy as durable and efficacious for maintaining virological suppression in HIV-1patients. Darunavir/ritonavir monotherapy should be considered as a (tailored) treatment option for standard triple-therapy patients who have had a substantial period of viral suppression.
Authors: Gaetana Sterrantino; Mauro Zaccarelli; Antonio Di Biagio; Maria Luisa Biondi; Andrea Antinori; Giovanni Penco Journal: Infection Date: 2015-03-28 Impact factor: 3.553
Authors: Angela Gutierrez-Liarte; Ana Gomez-Berrocal; Carmen Saez; Jorge Valencia; Ignacio Santos; Jesus Sanz Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396
Authors: Luis F López-Cortés; Manuel A Castaño; Miguel A López-Ruz; María J Rios-Villegas; José Hernández-Quero; Dolores Merino; Patricia Jiménez-Aguilar; Manuel Marquez-Solero; Alberto Terrón-Pernía; Francisco Tellez-Pérez; Pompeyo Viciana; Francisco Orihuela-Cañadas; Zaira Palacios-Baena; David Vinuesa-Garcia; Jose M Fajardo-Pico; Alberto Romero-Palacios; Guillermo Ojeda-Burgos; Juan Pasquau-Liaño Journal: PLoS One Date: 2016-02-12 Impact factor: 3.240
Authors: Sidonie Lambert-Niclot; Philippe Flandre; Marc-Antoine Valantin; Cathia Soulie; Slim Fourati; Marc Wirden; Sophie Sayon; Sophie Pakianather; Laurence Bocket; Bernard Masquelier; Georges Dos Santos; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin Journal: PLoS One Date: 2012-07-25 Impact factor: 3.240